share_log

Transcode Therapeutics | 8-K: Current report

Transcode Therapeutics | 8-K: Current report

Transcode Therapeutics | 8-K：重大事件
美股SEC公告 ·  06/13 17:09

Moomoo AI 已提取核心訊息

TransCode Therapeutics, Inc. held its 2024 Annual Meeting of Stockholders on June 13, 2024, where several key proposals were voted upon. The meeting saw the election of four directors, Philippe P. Calais, PhD, Thomas A. Fitzgerald, Erik Manting, PhD, and Magda Marquet, PhD, each for a one-year term. Additionally, stockholders approved an amendment to increase the number of shares available under the company's 2021 Stock Option and Incentive Plan by 3,000,000 shares. The appointment of WithumSmith+Brown, PC as the independent registered public accounting firm for the fiscal year ending December 31, 2024, was ratified. However, the proposal for a reverse stock split of common stock by a ratio between 1-for-2 and 1-for-40 was not approved. An adjournment proposal was passed in case there were insufficient votes to approve the reverse stock split or the stock plan amendment, but it was not needed as the latter was approved. The total number of shares entitled to vote was 6,108,053, with 2,392,577 shares present or represented by proxy.
TransCode Therapeutics, Inc. held its 2024 Annual Meeting of Stockholders on June 13, 2024, where several key proposals were voted upon. The meeting saw the election of four directors, Philippe P. Calais, PhD, Thomas A. Fitzgerald, Erik Manting, PhD, and Magda Marquet, PhD, each for a one-year term. Additionally, stockholders approved an amendment to increase the number of shares available under the company's 2021 Stock Option and Incentive Plan by 3,000,000 shares. The appointment of WithumSmith+Brown, PC as the independent registered public accounting firm for the fiscal year ending December 31, 2024, was ratified. However, the proposal for a reverse stock split of common stock by a ratio between 1-for-2 and 1-for-40 was not approved. An adjournment proposal was passed in case there were insufficient votes to approve the reverse stock split or the stock plan amendment, but it was not needed as the latter was approved. The total number of shares entitled to vote was 6,108,053, with 2,392,577 shares present or represented by proxy.
TransCode Therapeutics公司於2024年6月13日舉行了2024年股東大會，在會上投票表決了多項關鍵提案。該會議選舉了四位董事，Philippe P. Calais、Thomas A. Fitzgerald、Erik Manting及Magda Marquet，任期均爲一年。此外，股東批准修訂公司2021年股票期權和激勵計劃，增加300萬股的股份。WithumSmith+Brown、PC被任命爲獨立註冊公共會計師，負責2024年12月31日結束的財政年度審計。然而，普通股票的反向拆股提案並未獲得通過，拆股比例爲1比2至1比40。即使可供表決的股數不足，也通過了一項提案以延期投票，以便批准拆股或股票計劃修正案，但後者已經獲得批准。有表決權的股份數量爲6,108,053股，代理或出席會議的股東有2,392,577股。
TransCode Therapeutics公司於2024年6月13日舉行了2024年股東大會，在會上投票表決了多項關鍵提案。該會議選舉了四位董事，Philippe P. Calais、Thomas A. Fitzgerald、Erik Manting及Magda Marquet，任期均爲一年。此外，股東批准修訂公司2021年股票期權和激勵計劃，增加300萬股的股份。WithumSmith+Brown、PC被任命爲獨立註冊公共會計師，負責2024年12月31日結束的財政年度審計。然而，普通股票的反向拆股提案並未獲得通過，拆股比例爲1比2至1比40。即使可供表決的股數不足，也通過了一項提案以延期投票，以便批准拆股或股票計劃修正案，但後者已經獲得批准。有表決權的股份數量爲6,108,053股，代理或出席會議的股東有2,392,577股。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間